Abstract P5-04-17: From transcriptome meta-analysis to targeted therapies in triple negative breast cancer

Triple-Negative Breast Cancer (TNBC) is a subtype of breast cancer that urgently requires the identification and approval of novel targeted therapies. Even for breast cancer subtypes that have approved targeted therapies such as tamoxifen in ER+ and herceptin in HER2+ patients, there are a proportion of patients that do not respond to these therapies or develop resistance and succumb to metastatic recurrence. Thus, there is a clinical need to identify patients who do not benefit from current standard therapies and developing new strategies for therapy for non-responsive patients across all breast cancer subtypes.We hypothesised a potential prognostic and drug discovery approach by meta-analysis of multiple global gene expression profiles of breast cancer studies to identify significantly over- and under-expressed genes that associate with clinical outcomes (metastatic and/or death events within five years). These genes were filtered through 3 methods to annotate their predicted functions (1). The third and most generalised method identified a 133-gene signature set that was prognostic in all subtypes of breast cancer. These signatures, particularly with the devised score calculated as the ratio of the average expression of the over-expressed genes to the under-expressed genes, were patented (2). Of the 133 genes, we selected a 21-gene list representing novel and new targets in breast cancer drug development. The 21 genes were selected through an unbiased ranking of least-publ...
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Poster Session Abstracts Source Type: research